Skip to Main Content

Try STAT+ TODAY

drug prices

Most Read

Pharmalot Ed Silverman

A drug maker replaces an old treatment and boosts the price by 1,300%

Pharmalot Ed Silverman

Those high-priced CAR-T therapies are actually cost effective

The Pharmalot View Ed Silverman

The art of the deal? Why a money-back guarantee for drugs is a bad idea

Pharmalot Ed Silverman

High prices for some leukemia drugs will make them less cost-effective

First Opinion James R. Baker Jr.

EpiPen pricing controversy reflects larger issues in pharma industry

Pharmalot Ed Silverman

The curious case of the $9,500 skin gel

Pharmalot Ed Silverman

Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says

Business Associated Press

The pros and cons of drug coupon cards

All Coverage

First Opinion Ed Schoonveld

If 2021 is to be the year of U.S. drug price controls, how should biopharma companies respond?

First Opinion Michael Mandel

The ‘prescription escalator’ may be to blame for rising out-of-pocket drug spending

advertisement

Politics Lev Facher

In a pivotal race in North Carolina, Democrats try to paint the incumbent as ‘pharma’s favorite senator’

Politics Lev Facher and Nicholas Florko

Sensing an advantage, Democrats dare Trump to talk drug prices during State of the Union

Pharmalot Ed Silverman

Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial

Pharmalot Ed Silverman

Doctors Without Borders demands drug makers lower their prices for TB treatments

Pharmalot Ed Silverman

A compounder loses a battle with the FDA over using bulk substances

Politics Lev Facher and Nicholas Florko

Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses

Politics Lev Facher

Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’

Pharmalot Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Politics Lev Facher

Kamala Harris becomes the latest Democratic candidate to zero in on drug prices

Pharmalot Ed Silverman

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

Pharmalot Ed Silverman

AIDS groups criticize Express Scripts for excluding several HIV medicines

Pharmalot Ed Silverman

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot Ed Silverman

Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ Conn. prosecutor says

Pharmalot Ed Silverman

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

First Opinion John Arnold

John Arnold: Trump administration’s good effort on drug rebates is bad policy

Pharmalot Ed Silverman

Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices

Pharmalot Ed Silverman

Lilly discloses pricing data on insulin in response to political pressure

Pharmalot Ed Silverman

Vertex CEO says he will bring ‘new ideas’ to break a stalemate in the U.K. over a cystic fibrosis drug

Pharmalot Ed Silverman

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

Pharmalot Ed Silverman

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

Pharmalot Ed Silverman

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

Pharmalot Ed Silverman

Vertex faces more pressure over pricing, but one analyst does not expect any movement

Pharmalot Ed Silverman

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan